Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.46 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.45 |
| ▸ | MITF | O75030 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.45 |
| ▸ | NCF1 | P14598 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14588005 | 0.93 | L3MBTL1 (0.61) | L3MBTL1SMN1; SMN2TP53HTTLMNA | |
| SCHEMBL14588039 | 0.88 | EHMT2 (0.49) | L3MBTL1SMN1; SMN2TP53HTTLMNA | |
| SCHEMBL14588025 | 0.86 | L3MBTL1 (0.53) | L3MBTL1SMN1; SMN2TP53HTTLMNA | |
| SCHEMBL14588029 | 0.85 | L3MBTL1 (0.52) | L3MBTL1SMN1; SMN2TP53HTTLMNA | |
| SCHEMBL14588037 | 0.83 | TP53 (0.54) | SMN1; SMN2TP53PTPN11OPRL1MAPT | |
| SCHEMBL14588082 | 0.81 | L3MBTL1 (0.48) | L3MBTL1SMN1; SMN2TP53HTTLMNA | |
| SCHEMBL14588028 | 0.80 | SMN1; SMN2 (0.56) | L3MBTL1SMN1; SMN2TP53HTTLMNA | |
| SCHEMBL14588014 | 0.80 | EHMT2 (0.55) | L3MBTL1SMN1; SMN2TP53HTTLMNA | |
| SCHEMBL14588020 | 0.80 | TP53 (0.49) | L3MBTL1SMN1; SMN2TP53LMNAPTPN11 | |
| SCHEMBL14588035 | 0.79 | L3MBTL1 (0.46) | L3MBTL1SMN1; SMN2TP53HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1613322-A4 | AMINOQUINOLINE COMPOUNDS | TAIGEN BIOTECHNOLOGY CO LTD (TW) | 2008-08-13 | — | — | EP | disclosed |
| US-7183413-B2 | Aminoquinoline compounds | TAIGEN BIOTECHNOLOGY (TW) | 2007-02-27 | — | — | US | disclosed |
| EP-1613322-A2 | AMINOQUINOLINE COMPOUNDS | Taigen Biotechnology (TW) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004091485-A2 | AMINOQUINOLINE COMPOUNDS | TAIGEN BIOTECHNOLOGY (TW) | 2004-10-28 | — | — | WO | disclosed |
| US-20040209902-A1 | e.g., 1,4-bis[2,6-dimethylquinolin-4ylamino]butane; used to treat inflammatory and immune diseases by binding to CXCR3 receptors. | TAIGEN BIOTECHNOLOGY (TW) | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209902-A1 | e.g., 1,4-bis[2,6-dimethylquinolin-4ylamino]butane; used to treat inflammatory and immune diseases by binding to CXCR3 receptors. | CXCR3, CXCL10, CXCR1 | L3MBTL1 1815/4885SMN1; SMN2 4781/4885TP53 2907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.